In the scratch assay, BAZE-X1, like tocilizumab, exhibited antimigratory effects against LLSCC1 but not against SCC13. However, in the context of 3D models (SCC13, LSCLC1, and FaDu), BAZE-X1 (1.0 and especially 5.0 µmol/L; 2.65 and 0.53 µg/mL) displayed a potent antimigration effect.

In this cohort, tocilizumab significantly reduced 30-day mortality overall. Although the number of Hyperinflammatory patients was low, there was no evidence that its efficacy differed between inflammatory subphenotypes. These findings underscore the importance of including both subphenotypes in future trials evaluating the differential effects of tocilizumab.

P1/2, N=156, Not yet recruiting, Oslo University Hospital HF

[177Lu]Lu-DOTA-Tocilizumab represents a potential theranostic agent for MM. Therefore, we expect this agent to open the way to new diagnostic and therapeutic strategies for this devastating disease.

We describe a 71-year-old man with a 16-year history of RA who developed destructive thyroiditis after initiation of certolizumab pegol...Treatment with the IL-6 receptor antibody tocilizumab rapidly normalized inflammatory markers and improved both renal function and gastrointestinal symptoms. This case highlights that TNF-α inhibition may paradoxically unmask underlying amyloidosis and induce autoimmune thyroiditis. Clinicians should monitor thyroid and systemic amyloid markers when introducing biologic therapy for long-standing RA.

P1/2, N=65, Recruiting, University of Southern California | Trial completion date: Sep 2027 --> May 2027

Pharmacological agents like metformin, SGLT2 inhibitors, and statins demonstrate promising anticancer effects in addition to glycemic control, while biologics such as canakinumab and tocilizumab modulate inflammatory processes relevant to both disease states. Ultimately, dual-targeting strategies represent an emerging and promising therapeutic framework for managing patients with overlapping cancer and metabolic disease, with potential to optimize outcomes, reduce therapy-related toxicities, improve long-term survival. Future research must prioritize biomarker-guided precision therapies, multidisciplinary management and the inclusion of metabolic parameters in oncology trial designs.

P2, N=38, Recruiting, Nationwide Children's Hospital | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2027

P1/2, N=28, Active, not recruiting, F. Hoffmann-La Roche AG | Recruiting --> Active, not recruiting

Our study identifies fibroblast-immune cell interactions, particularly IL-6-mediated fibroblast-macrophage crosstalk, as a key mechanism in radioimmunotherapy-induced cardiac fibrosis. Tocilizumab, an IL-6R inhibitor, demonstrates therapeutic potential to attenuate this cardiotoxicity.

P1, N=9, Active, not recruiting, University of Colorado, Denver | Trial completion date: Dec 2025 --> May 2027

P1, N=7, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=72 --> 7 | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027